Combining SERS analysis of serum with PSA levels for improving the detection of prostate cancer

Previous studies regarding surface-enhanced Raman scattering (SERS) of serum have shown promising initial results in discriminating prostate cancer, a strategy which could complement standard tests such as the prostate-specific antigen (PSA). SERS spectra of serum samples were combined with serum PS...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine (London, England) England), 2018-10, Vol.13 (19), p.2455-2467
Main Authors: Stefancu, Andrei, Moisoiu, Vlad, Couti, Razvan, Andras, Iulia, Rahota, Razvan, Crisan, Dana, Pavel, Ioana E, Socaciu, Carmen, Leopold, Nicolae, Crisan, Nicolae
Format: Article
Language:English
Subjects:
Accuracy
Aged
Antigens
Biomarkers
Discriminant Analysis
Disease
drop coating deposition
Early Detection of Cancer
Gold
Humans
Male
Medical diagnosis
Medical screening
Middle Aged
Molecular structure
Nanoparticles
Neoplasm Grading
Ovarian cancer
Principal Component Analysis
principal component analysis-linear discriminant analysis
Principal components analysis
Prostate cancer
prostate-specific antigen
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - pathology
screening
serum
Spectrum analysis
Spectrum Analysis, Raman
Studies
surface-enhanced Raman scattering
Tumors
Urine
Urogenital system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous studies regarding surface-enhanced Raman scattering (SERS) of serum have shown promising initial results in discriminating prostate cancer, a strategy which could complement standard tests such as the prostate-specific antigen (PSA). SERS spectra of serum samples were combined with serum PSA levels to improve the discrimination accuracy between prostate cancer and nonmalignant pathologies in a cohort of 54 patients using principal component analysis-linear discriminant analysis (PCA-LDA). Combining SERS spectra with serum PSA levels in a single PCA-LDA model could discriminate between the two groups with an overall accuracy of 94%, yielding better results than either method alone. These results highlight that combining SERS-based cancer screening with serum PSA levels represents a promising strategy for improving the accuracy of prostate cancer diagnosis.
ISSN:1743-5889
1748-6963
DOI:10.2217/nnm-2018-0127